Moreover, we demonstrate that targeting SPAG9, which is expressed together with HLA-G in primary lung cancer cells, is sufficient to impede BM establishment despite the presence of HLA-G in these cells, signifying a potential preventive therapeutic role for an HLA-G intermediary partner in primary cancers with a predilection for BM. This evidence concerns the gene SPAG9 and lung cancer.